Inactive Instrument

Epizyme, Inc.

Equities

EPZM

US29428V1044

Biotechnology & Medical Research

Epizyme, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020

February 23, 2021 at 06:30 am EST

Epizyme, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced total revenue was USD 8.375 million compared to USD 4.294 million a year ago. Operating loss was USD 62.145 million compared to USD 57.493 million a year ago. Net loss was USD 66.233 million compared to USD 56.402 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.59 a year ago. For the full year, total revenue was USD 15.762 million compared to USD 23.800 million a year ago. Operating loss was USD 225.416 million compared to USD 177.142 million a year ago. Net loss was USD 231.694 million compared to USD 170.295 million a year ago. Basic loss per share from continuing operations was USD 2.29 compared to USD 1.93 a year ago.

Latest news about Epizyme, Inc.

France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme	22-08-14	MT
Epizyme Announces Management Changes	22-08-12	CI
Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer	22-08-12	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Composite Index	22-08-12	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index	22-08-12	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P TMI Index	22-08-12	CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Biotechnology Index	22-08-11	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Management LLC and others.	22-08-10	CI
Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M	22-08-09	MT
Epizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
France's Ipsen Extends Tender Offer To Purchase US Biopharmaceutical Epizyme	22-08-05	MT
Hutchmed Starts Bridging Study Follicular Lymphoma Treatment in China	22-08-01	MT
North American Morning Briefing : Futures Waver -2-	22-06-29	DJ
Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50	22-06-28	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	22-06-27	MT
Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations	22-06-27	MT
Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer	22-06-27	MT
Top Premarket Gainers	22-06-27	MT
Transcript : Epizyme, Inc., Ipsen S.A. - M&A Call	22-06-27
European shares hit two-week high as China eases COVID-19 curbs	22-06-27	RE
Epizyme Agrees to be Acquired by Ipsen for $247 Million	22-06-27	MT
France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme	22-06-27	MT
Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. from RP Management LLC and others for approximately $250 million.	22-06-26	CI
HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating	22-06-03	MT
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting	22-06-02	CI

Chart Epizyme, Inc.

Duration

Period

More charts

Company Profile

Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.73%	102B
REGENERON PHARMACEUTICALS, INC.	+2.56%	96.07B
ARGENX SE	-1.25%	21.66B
BIONTECH SE	-18.13%	20.77B
GENMAB A/S	-7.31%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-28.42%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.78%	13.33B
SAREPTA THERAPEUTICS, INC.	+21.32%	10.94B

Bio Therapeutic Drugs